DMT-dG(iBu)-CE Reverse Phosphoramidite
DMT-dG(iBu)-CE Reverse Phosphoramidite - N (Normal) is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
Shipping notes
Shipping notes
Related Products
Specifications
Specifications
-
Catalog No.PD2-007
-
SMILESN#CCCOP(N(C(C)C)C(C)C)OC[C@H]1O[C@@H](N(C=N2)C3=C2C(NC(NC(C(C)C)=O)=N3)=O)C[C@@H]1OC(C4=CC=C(OC)C=C4)(C5=CC=CC=C5)C6=CC=C(OC)C=C6
-
Molecular FormulaC44H54N7O8P
-
Molecular Weight839.92
-
AppearanceWhite to faint yellow powder
-
PurityHPLC≥98.0%
-
Storage Condition-20℃
Documentation
Documentation
-
Catalog No.PD2-007
-
SMILESN#CCCOP(N(C(C)C)C(C)C)OC[C@H]1O[C@@H](N(C=N2)C3=C2C(NC(NC(C(C)C)=O)=N3)=O)C[C@@H]1OC(C4=CC=C(OC)C=C4)(C5=CC=CC=C5)C6=CC=C(OC)C=C6
-
Molecular FormulaC44H54N7O8P
-
Molecular Weight839.92
-
AppearanceWhite to faint yellow powder
-
PurityHPLC≥98.0%
-
Storage Condition-20℃
Why choose Hongene?
Trusted Partner in Nucleic Acid
Integrated Supply & Commercial Scale
With 26+ years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.
Proprietary Technology & IP
Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.
Rigorous Quality
We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.
Manufacturing Scalability
Hongene operates 1.67 million sq. ft Oligonucleotide Manufacturing Facility, with advanced equipments including multiple OligoPilot™ and OligoProcess™ synthesizers (10-1800 mmol). 48 flexible production lines enable one-stop seamless scaling-up of API production from gram-level to tons and acheive high purity of 98%, meeting NMPA, FDA, and EMA standards.
Global Business Network
Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.
